Volume: 56 Issue: 3
Year: 2025, Page: 393-399, Doi: https://doi.org/10.51966/jvas.2025.56.3.393-399
Received: March 18, 2025 Accepted: Aug. 11, 2025 Published: Sept. 30, 2025
Cancer remains one of the leading causes of death worldwide, largely due to the lack of effective therapeutic options for advanced stages of the disease. Over the past few decades, a variety of cancer treatment regimens have been explored. Among them, oncolytic virus therapy has emerged as an exciting and increasingly prominent field in cancer research. Several oncolytic viruses have been extensively studied, with Newcastle disease virus (NDV) standing out as a particularly promising agent for targeting cancer cells. The NDV exhibits selective cytotoxicity against tumour cells and is also capable of stimulating immune responses. Numerous strategies have been developed to employ NDV as a virotherapeutic agent, yielding variable outcomes. This paper reviews the various aspects of NDV virotherapy in human cancers, highlighting recent advancements and progress in clinical trials.
Keywords: Newcastle Disease Virus, cancer, oncolytic, virotherapy
Aghi, M., Visted, T., Depinho, R. A. and Chiocca, E.A. 2008. Oncolytic Herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene. 27(30):4249-4254.
Cassel, W.A., Murray, D.R., Torbin, A.H., Olkowski, Z.L. and Moore, M.E. 1977. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer. 40: 672-679.
Cook, M. and Chauhan, A., 2020. Clinical application of oncolytic viruses: a systematic review. International journal of molecular sciences, 21(20): 7505.
Csatary, L. K. 1971. Viruses in the treatment of cancer. Lancet. 2: 825.
Csatary, L.K., Eckhard, S., Bukosza, I., Czegledi, F., Fenyvesi, C., Gergely, P., Bodey, B. and Csatary, C.M. 1993. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prev. 17: 619–627.
Csatary, L.K., Gosztonyi, G., Szeberenyi, J., Fabian, Z., Liszka, V., Bodey, B. and Csatary, C.M. 2004. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neuro Oncol. 67 : 83–93.
De pace n Sulla. 1912. scomparsa di un enorme cancro vegetante del collo dell’utero senza cura chirurgica. [On the demise of the huge vegetating cervical cancer without surgical care]. Ginecologia. 9:82–89.
Fenton, S.E., Saleiro, D. and Platanias, L.C. 2021. Type I and II interferons in the anti-tumour immune response. Cancers.13(5):1037.
Fournier, P., Arnold, A., Wilden, H. and Schirrmacher, V. 2012. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int. J. Oncol. 40: 840–850.
Kaufman, H.L., Kohlhapp, F.J. and Zloza, A. 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 14(9): 642-662.
Koks, C.A., Garg, A.D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., De Vleeschouwer, S., Agostinis, P., Graf, N. and Van Gool, S.W. 2015. Newcastle disease virotherapy induces long-term survival and tumour-specific immune memory in ortheotopic glioma through the induction of immunogenic cell death. Int. J. Cancer. 13(6): 313–325.
Kroemer, G., Galuzzi, I., Kepp, O. and Zitvogel, I. 2013. Immunogenic cell death in cancer therapy. Ann. Rev. Immunol. 31: 51–72.
Lam, H.Y., Yeap, S.K., Rasoli, M., Omar, A.R., Yusoff, K., Suraini, A.A. and Banu Alitheen, N., 2011. Safety and clinical usage of Newcastle disease virus in cancer therapy. BioMed ResInt. 718710.
Lemos de Matos, A., Franco, L.S. and McFadden, G. 2020. Oncolytic viruses and the immune system: The dynamic duo. Mol Ther Methods Clin Dev. 17: 349‑358.
Li, Y.L., Wu, J., Wie, D., Zhang, D.W., Feng, H., Chen, Z.N. and Bian, H. 2009. Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice. Liver Int. 29: 593–602.
Lin, D., Shen, Y., and Liang, T. 2023. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct. Target. Ther. 8: 156.
Lindenmann, J.1974. Viruses as immunological adjuvants in cancer. Biochem. Biophys. Acta, 35:49-75.
Miller, P.J. and Koch, G. 2013. Newcastle disease. In Diseases of Poultry, 13th ed.; Swayne, D.E., Glisson, J.R., McDougald, L.R., Nolan, L.K., Suarez, D.L., Nair, V.L., Eds.; Wiley-Blackwell: Hoboken, NJ, USA. pp. 89–138.
Moaven, O., Mangieri, C.W., Stauffer, J.A., Anastasiadis, P.Z. and Borad, M.J., 2021. Strategies to develop potent oncolytic viruses and enhance their therapeutic efficacy. JCO prec onc. 5:733-743.
Pei Y, Sun Y, Chen J, et al. 2024. Oncolytic properties and direct antitumor efficacy of a recombinant velogenic Newcastle Disease Virus (Italien strain) in immunodeficient murine models. Cancer Gene Ther. 31(2):89–102.
Rodrigues, M.C., Morais, J.A.V., Ganassin, R., Oliveira, G.R.T., Costa, F.C., Morais, A.A.C., Silveira, A.P., Silva, V.C.M., Longo, J.P.F. and Muehlmann, L.A., 2022. An overview on immunogenic cell death in cancer biology and therapy. Pharmaceutics. 14(8):1564.
Samal, K.S., 2011. Newcastle disease and related avian paramyxoviruses. In The Biology of Paramyxoviruses, 1st ed.; Samal, S.K., Ed.; Caister Academic Press: Norfolk, UK,; pp. 69–114.
Schirrmacher, V., Ahlert, T., Pröbstle, T., Steiner, H.H., Herold-mende, C., Gerhards, R., Hagmüller, E. and Steiner, H.H. 1998. Immunization with virus-modified tumour cells. Semin. Oncol., 25:677-696.
Schirrmacher, V., Stuecker, W., Lulei, M., Bihari, A.S. and Sprenger, T. 2015. Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: A case report. Immunotherapy. 7: 855–860.
Schirrmacher, V., van Gool, S. and Stuecker, W., 2022. Counteracting immunosuppression in the tumour microenvironment by oncolytic Newcastle disease virus and cellular immunotherapy. Int J Mol Sci. 23(21):13050.
Shalhout, S.Z., Miller, D.M., Emerick, K.S., and Kaufman, H.L. 2023. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20: 160–177.
Tayeb, S., Zakay-Rones, Z. and Panet, A., 2015. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic virotherapy.49-62.
Tsuchida, T., Friedman, S. Mechanisms of hepatic stellate cell activation. 2017. Nat Rev Gastroenterol Hepatol. 14, 397–411.
Wang, L., Dunmall, L.S.C., Cheng, Z. and Wang, Y. 2022. Remodeling the tumour microenvironment by oncolytic viruses: beyond oncolysis of tumour cells for cancer treatment. J Immunother Cancer.10(5): 004167.
Wheelock, E. F. and Dingle, J. H. 1964. Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N. Engl. J. Med. 27(1): 645-651.
Yang, L., Gu, X., Yu, J., Ge, S. and Fan, X., 2021. Oncolytic virotherapy: From bench to bedside. Front.Cell Develop. Biol., 9: e.790150.
Ye, T., Jiang, K., Wei, L., Barr, M.P., Xu, Q., Zhang, G., Ding, C., Meng, S. and Piao, H. 2018. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am J cancer Res. 8(8):1514.
Younossi, Z.M., Wong, G., Anstee, Q.M. and Henry, L. 2023. The global burden of liver disease. Clin Gastroenterol Hepatol. 21(8):1978-1991.
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y. and Li, Y. 2021. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal transduct. target.ther., 6(1):263-308.
Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, Peng H, Deng Z, Xiao G, Liu X, Na J, Xia D, Yu X, Zhang Z, Xiang B, Huo Y, Yan D, Dong Z, Fang F, Ma Y, Jin G, Su D, Liu X, Li Q, Liao H, Tang C, He J, Tang Z, Zhang S, Qiu B, Yang Z, Yang L, Chen Z, Zeng M, Feng R, Jiao J, Liao Y, Wang T, Wu L, Mi Z, Liu Z, Shi S, Zhang K, Shi W, Zhao Y. 2025. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 20;188(4):1119-1136.
© 2025 Deepthi. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Deepthi, B. 2025. Growing promise of oncolytic virotherapy: opportunities and pitfalls of NDV in cancer therapy.
J. Vet. Anim. Sci. 56 (3):393-399